Key facts
- This page summarizes Daniel Joseph OConnell's Form 3 filing for Acumen Pharmaceuticals, Inc. (ABOS).
- 0 reported transactions and 8 derivative rows are listed below.
- Accepted by SEC: 30 Jun 2021, 18:51.
Daniel Joseph OConnell - 30 Jun 2021 Form 3 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- ABOS
- Reported as of
- 30 Jun 2021
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 30 Jun 2021, 18:51:03 UTC
- Next SEC filing
- 08 Jul 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Katherine Denby, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Daniel Joseph OConnell filed Form 3 for Acumen Pharmaceuticals, Inc. (ABOS) on 30 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ABOS
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,419
- Date
- 30 Jun 2021
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ABOS
holding
Derivative
Series A Preferred Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 30 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 123
- Exercise price
- Footnotes
- F1
ABOS
holding
Derivative
Warrant (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 30 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 35
- Exercise price
- $2.01
- Footnotes
- F2
ABOS
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 30 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,118
- Exercise price
- $4.47
- Footnotes
- F2
ABOS
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 30 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 197
- Exercise price
- $22.39
- Footnotes
- F2
ABOS
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 30 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 33,567
- Exercise price
- $4.47
- Footnotes
- F2
ABOS
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 30 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,527
- Exercise price
- $4.47
- Footnotes
- F2
ABOS
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 30 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 418,903
- Exercise price
- $0.7200
- Footnotes
- F3
ABOS
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 30 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,186,346
- Exercise price
- $1.19
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Each share of Series A Preferred Stock will automatically convert into one share of Common Stock of the Issuer upon the closing of the Issuer's initial public offering. The Series A Preferred Stock has no expiration date.
Footnote F2
Immediately exercisable.
Footnote F3
The shares underlying the option vest and become exercisable in 36 equal monthly installments beginning on November 19, 2018, such that the option shall be fully vested on October 19, 2021, subject to the Reporting Person providing continuous service to the Issuer on each such date.
Footnote F4
25% of the shares underlying the option shall vest and become exercisable on January 1, 2022; the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, such that the option shall be fully vested on January 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such date.
SEC remarks
Exhibit List - Exhibit 24 - Power of Attorney